Join to View Full Profile
8081 Innovation Park DrFairfax, VA 22031
Phone+1 571-472-4724
Fax+1 571-472-1601
Dr. Maitland is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2003 - 2005
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2003
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2000 - 2002
Albert Einstein College of MedicineClass of 2000
Certifications & Licensure
VA State Medical License 2016 - 2026
IL State Medical License 2003 - 2017
NY State Medical License 2002 - 2004
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Sorafenib in Treating Patients With Advanced Solid Tumors Start of enrollment: 2007 Jan 01
- INNO-206 in Patients With Small Cell Lung Cancer (SCLC) Start of enrollment: 2008 May 01
- Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC Start of enrollment: 2010 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities.Sanja Karovic, Erik Dvergsten, Chiara Pierattini, Ana Barac, Lauren Fay
Cancer Research Communications. 2025-06-01 - 3 citationsModel-based approach to identify predictors of paclitaxel-induced myelosuppression in "real-world" administration.Ahmed M Salem, Erik Dvergsten, Sanja Karovic, Michael L Maitland, Mathangi Gopalakrishnan
CPT. 2023-07-01 - 19 citationsPertuzumab Plus Trastuzumab in Patients With Endometrial Cancer WithAmplification, Overexpression, or Mutation: Results From the TAPUR Study.Eugene R Ahn, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Hussein M Ali-Ahmad
JCO Precision Oncology. 2023-04-01
Press Mentions
Public-Private Research Effort to Develop More Accurate Ways of Measuring Cancer ProgressionMarch 27th, 2017- Shop TalkSeptember 25th, 2016
Shop TalkSeptember 20th, 2016- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
